
Andrew P. Lee
Examiner (ID: 4275, Phone: (571)270-1016 , Office: P/1621 )
| Most Active Art Unit | 1621 |
| Art Unit(s) | 1691, 1621, 1628, 1629 |
| Total Applications | 702 |
| Issued Applications | 283 |
| Pending Applications | 98 |
| Abandoned Applications | 332 |
Applications
| Application number | Title of the application | Filing Date | Status |
|---|---|---|---|
Array
(
[id] => 17759892
[patent_doc_number] => 20220233504
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2022-07-28
[patent_title] => PHARMACEUTICAL COMPOSITION COMPRISING LIDOCAINE AND MELATONIN
[patent_app_type] => utility
[patent_app_number] => 17/488241
[patent_app_country] => US
[patent_app_date] => 2021-09-28
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 13539
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -18
[patent_words_short_claim] => 16
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17488241
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/488241 | PHARMACEUTICAL COMPOSITION COMPRISING LIDOCAINE AND MELATONIN | Sep 27, 2021 | Abandoned |
Array
(
[id] => 17342081
[patent_doc_number] => 20220008412
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2022-01-13
[patent_title] => KETAMINE OR DEXTROMETHORPHAN FORMULATIONS AND METHODS OF USE
[patent_app_type] => utility
[patent_app_number] => 17/449196
[patent_app_country] => US
[patent_app_date] => 2021-09-28
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 8652
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -24
[patent_words_short_claim] => 50
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17449196
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/449196 | Ketamine or dextromethorphan formulations and methods of use | Sep 27, 2021 | Issued |
Array
(
[id] => 17503304
[patent_doc_number] => 20220096406
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2022-03-31
[patent_title] => METHODS OF TREATING NEURODEGENERATIVE DISORDERS IN A PARTICULAR POPULATION
[patent_app_type] => utility
[patent_app_number] => 17/477886
[patent_app_country] => US
[patent_app_date] => 2021-09-17
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 10398
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -13
[patent_words_short_claim] => 32
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17477886
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/477886 | METHODS OF TREATING NEURODEGENERATIVE DISORDERS IN A PARTICULAR POPULATION | Sep 16, 2021 | Abandoned |
Array
(
[id] => 18108107
[patent_doc_number] => 20230000987
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2023-01-05
[patent_title] => FORMULATIONS AND USES THEREOF
[patent_app_type] => utility
[patent_app_number] => 17/467976
[patent_app_country] => US
[patent_app_date] => 2021-09-07
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 57133
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -17
[patent_words_short_claim] => 85
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17467976
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/467976 | Formulations and uses thereof | Sep 6, 2021 | Issued |
Array
(
[id] => 17297945
[patent_doc_number] => 20210393784
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2021-12-23
[patent_title] => INJECTABLE CANNABINOID FORMULATIONS FOR TREATING PAIN
[patent_app_type] => utility
[patent_app_number] => 17/466087
[patent_app_country] => US
[patent_app_date] => 2021-09-03
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 6596
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -9
[patent_words_short_claim] => 43
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17466087
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/466087 | INJECTABLE CANNABINOID FORMULATIONS FOR TREATING PAIN | Sep 2, 2021 | Abandoned |
Array
(
[id] => 18690891
[patent_doc_number] => 20230321053
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2023-10-12
[patent_title] => (1R,3S)-3-((5-CYANO-4-PHENYLTHIAZOL-2-YL)CARBAMOYL)CYCLOPENTANE-1-CARBOXYLIC ACID AND DERIVATIVES THEREOF FOR USE IN THE TREATMENT OF AIRWAY DISEASES
[patent_app_type] => utility
[patent_app_number] => 18/040508
[patent_app_country] => US
[patent_app_date] => 2021-08-20
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 9025
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -11
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18040508
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/040508 | (1R,3S)-3-((5-CYANO-4-PHENYLTHIAZOL-2-YL)CARBAMOYL)CYCLOPENTANE-1-CARBOXYLIC ACID AND DERIVATIVES THEREOF FOR USE IN THE TREATMENT OF AIRWAY DISEASES | Aug 19, 2021 | Pending |
Array
(
[id] => 17272853
[patent_doc_number] => 20210379051
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2021-12-09
[patent_title] => METHODS FOR THE TREATMENT OF ABNORMAL INVOLUNTARY MOVEMENT DISORDERS
[patent_app_type] => utility
[patent_app_number] => 17/400194
[patent_app_country] => US
[patent_app_date] => 2021-08-12
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 41960
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -39
[patent_words_short_claim] => 139
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17400194
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/400194 | Methods for the treatment of abnormal involuntary movement disorders | Aug 11, 2021 | Issued |
Array
(
[id] => 17458658
[patent_doc_number] => 20220071962
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2022-03-10
[patent_title] => COMPOSITIONS AND METHODS FOR PROVIDING HEALTH BENEFITS IN AN ANIMAL
[patent_app_type] => utility
[patent_app_number] => 17/398499
[patent_app_country] => US
[patent_app_date] => 2021-08-10
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 7142
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -18
[patent_words_short_claim] => 36
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17398499
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/398499 | Compositions and methods for providing health benefits in an animal | Aug 9, 2021 | Issued |
Array
(
[id] => 18938120
[patent_doc_number] => 20240033259
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2024-02-01
[patent_title] => COMPOSITIONS AND METHODS FOR TREATING OR PREVENTING DISEASE ASSOCIATED WITH BETA CORONAVIRUS INFECTION
[patent_app_type] => utility
[patent_app_number] => 18/019959
[patent_app_country] => US
[patent_app_date] => 2021-08-06
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 7335
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -58
[patent_words_short_claim] => 27
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18019959
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/019959 | COMPOSITIONS AND METHODS FOR TREATING OR PREVENTING DISEASE ASSOCIATED WITH BETA CORONAVIRUS INFECTION | Aug 5, 2021 | Pending |
Array
(
[id] => 18509297
[patent_doc_number] => 20230225368
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2023-07-20
[patent_title] => INSECT LIFE CYCLE INTERRUPTION AGENT(LCIA) FORMULATIONS AND THEIR MANUFACTURE AND USE
[patent_app_type] => utility
[patent_app_number] => 18/022042
[patent_app_country] => US
[patent_app_date] => 2021-08-02
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 18090
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -16
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18022042
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/022042 | Insect life cycle interruption agent(LCIA) formulations and their manufacture and use | Aug 1, 2021 | Issued |
Array
(
[id] => 18938133
[patent_doc_number] => 20240033272
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2024-02-01
[patent_title] => USE OF CANNABIDIOL IN THE TREATMENT OF SEIZURES ASSOCIATED WITH HERPES SIMPLEX VIRUS
[patent_app_type] => utility
[patent_app_number] => 18/005838
[patent_app_country] => US
[patent_app_date] => 2021-07-15
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 5136
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -3
[patent_words_short_claim] => 17
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18005838
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/005838 | USE OF CANNABIDIOL IN THE TREATMENT OF SEIZURES ASSOCIATED WITH HERPES SIMPLEX VIRUS | Jul 14, 2021 | Abandoned |
Array
(
[id] => 20492617
[patent_doc_number] => 12534479
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2026-01-27
[patent_title] => Triazine compound and composition and use thereof
[patent_app_type] => utility
[patent_app_number] => 18/015381
[patent_app_country] => US
[patent_app_date] => 2021-07-09
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 22040
[patent_no_of_claims] => 4
[patent_no_of_ind_claims] => 1
[patent_words_short_claim] => 161
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18015381
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/015381 | Triazine compound and composition and use thereof | Jul 8, 2021 | Issued |
Array
(
[id] => 17214402
[patent_doc_number] => 20210347739
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2021-11-11
[patent_title] => INHIBITION OF OLIG2 ACTIVITY
[patent_app_type] => utility
[patent_app_number] => 17/367099
[patent_app_country] => US
[patent_app_date] => 2021-07-02
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 69024
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -16
[patent_words_short_claim] => 17
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17367099
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/367099 | Inhibition of Olig2 activity | Jul 1, 2021 | Issued |
Array
(
[id] => 17618400
[patent_doc_number] => 11337423
[patent_country] => US
[patent_kind] => B1
[patent_issue_date] => 2022-05-24
[patent_title] => None
[patent_app_type] => utility
[patent_app_number] => 17/363682
[patent_app_country] => US
[patent_app_date] => 2021-06-30
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 3808
[patent_no_of_claims] => 11
[patent_no_of_ind_claims] => 1
[patent_words_short_claim] => 19
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17363682
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/363682 | None | Jun 29, 2021 | Issued |
Array
(
[id] => 18509906
[patent_doc_number] => 20230225992
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2023-07-20
[patent_title] => LIQUID DISPERSIBLE CURCUMINOID COMPOSITIONS AND METHODS OF IMPROVING COGNITIVE FUNCTION
[patent_app_type] => utility
[patent_app_number] => 18/012382
[patent_app_country] => US
[patent_app_date] => 2021-06-27
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 9279
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -10
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18012382
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/012382 | Liquid dispersible curcuminoid compositions and methods of improving cognitive function | Jun 26, 2021 | Issued |
Array
(
[id] => 17140083
[patent_doc_number] => 20210308094
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2021-10-07
[patent_title] => CESSATION OF ANTI-DEPRESSANT MEDICATION
[patent_app_type] => utility
[patent_app_number] => 17/351590
[patent_app_country] => US
[patent_app_date] => 2021-06-18
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 3206
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -17
[patent_words_short_claim] => 70
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17351590
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/351590 | CESSATION OF ANTI-DEPRESSANT MEDICATION | Jun 17, 2021 | Abandoned |
Array
(
[id] => 18522895
[patent_doc_number] => 20230233544
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2023-07-27
[patent_title] => T-TYPE CALCIUM CHANNEL ENHANCER FOR TREATING TAF1 ASSOCIATED NEUROLOGICAL DEFECTS
[patent_app_type] => utility
[patent_app_number] => 18/001519
[patent_app_country] => US
[patent_app_date] => 2021-06-11
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 9292
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -14
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18001519
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/001519 | T-TYPE CALCIUM CHANNEL ENHANCER FOR TREATING TAF1 ASSOCIATED NEUROLOGICAL DEFECTS | Jun 10, 2021 | Pending |
Array
(
[id] => 18597147
[patent_doc_number] => 20230271939
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2023-08-31
[patent_title] => 4-ETHYNYLPYRIDINE DERIVATIVES USEFUL AS GCN2 INHIBITORS
[patent_app_type] => utility
[patent_app_number] => 18/001317
[patent_app_country] => US
[patent_app_date] => 2021-06-09
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 26719
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -29
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18001317
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/001317 | 4-ETHYNYLPYRIDINE DERIVATIVES USEFUL AS GCN2 INHIBITORS | Jun 8, 2021 | Pending |
Array
(
[id] => 18075823
[patent_doc_number] => 20220401435
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2022-12-22
[patent_title] => MRGPRX2 ANTAGONIST FOR THE TREATMENT OF PSEUDO ALLERGIC REACTIONS
[patent_app_type] => utility
[patent_app_number] => 17/334872
[patent_app_country] => US
[patent_app_date] => 2021-05-31
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 44558
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -34
[patent_words_short_claim] => 254
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17334872
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/334872 | MRGPRX2 ANTAGONIST FOR THE TREATMENT OF PSEUDO ALLERGIC REACTIONS | May 30, 2021 | Pending |
Array
(
[id] => 18466871
[patent_doc_number] => 20230201151
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2023-06-29
[patent_title] => FORMULATIONS AND METHODS FOR TREATING ACUTE RESPIRATORY DISTRESS SYNDROME, ASTHMA, OR ALLERGIC RHINITIS
[patent_app_type] => utility
[patent_app_number] => 18/000177
[patent_app_country] => US
[patent_app_date] => 2021-05-28
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 29854
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -19
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18000177
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/000177 | FORMULATIONS AND METHODS FOR TREATING ACUTE RESPIRATORY DISTRESS SYNDROME, ASTHMA, OR ALLERGIC RHINITIS | May 27, 2021 | Pending |